Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
EQ 
Equillium Inc (EQ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: EQ (3-star) is a STRONG-BUY. BUY since 43 days. Simulated Profits (8.07%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.33
1 Year Target Price $3.33
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 111.43M USD | Price to earnings Ratio - | 1Y Target Price 3.33 |
Price to earnings Ratio - | 1Y Target Price 3.33 | ||
Volume (30-day avg) 2 | Beta 1.85 | 52 Weeks Range 0.27 - 2.35 | Updated Date 02/26/2026 |
52 Weeks Range 0.27 - 2.35 | Updated Date 02/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -554.87% |
Management Effectiveness
Return on Assets (TTM) -44.17% | Return on Equity (TTM) -90.24% |
Valuation
Trailing PE - | Forward PE 1.53 | Enterprise Value 76233737 | Price to Sales(TTM) 25.37 |
Enterprise Value 76233737 | Price to Sales(TTM) 25.37 | ||
Enterprise Value to Revenue 4.61 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 60893283 | Shares Floating 29136218 |
Shares Outstanding 60893283 | Shares Floating 29136218 | ||
Percent Insiders 20.93 | Percent Institutions 58.11 |
Upturn AI SWOT
Equillium Inc
Company Overview
History and Background
Equillium Inc. was founded in 2017, emerging from the acquisition of Drako, Inc. by NantCell. Its primary focus is on developing novel therapeutics for autoimmune and inflammatory diseases. A significant milestone was its initial public offering (IPO) in 2018, enabling further investment in its pipeline. The company has evolved by prioritizing the clinical development of its lead assets and exploring new indications.
Core Business Areas
- Immunological Therapeutics: Equillium is dedicated to developing and commercializing transformative medicines for patients suffering from severe autoimmune and inflammatory diseases. Their core strategy revolves around modulating the activity of pathways critical to immune homeostasis.
Leadership and Structure
Equillium Inc. is led by a management team with extensive experience in biotechnology and pharmaceutical development. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments focused on research and development, clinical operations, regulatory affairs, manufacturing, and commercialization. Specific leadership roles and board members can be found in their investor relations materials and SEC filings.
Top Products and Market Share
Key Offerings
- TQ0302 (Iqbalizimab): TQ0302 (formerly itolizumab) is a monoclonal antibody targeting CD6, a receptor critical for T-cell activation and trafficking. It is being investigated for various autoimmune and inflammatory conditions, including lupus nephritis, graft-versus-host disease (GVHD), and alopecia areata. Competitors in the autoimmune and inflammatory disease space are numerous, including companies developing biologics targeting cytokines, B-cells, and other immune pathways. Specific market share data for TQ0302 is not yet available as it is in clinical development.
- TQG121: TQG121 is a small molecule inhibitor of the Toll-like receptor 7 (TLR7) pathway, which plays a role in innate immune responses and can contribute to autoimmune diseases. It is being explored for systemic lupus erythematosus (SLE) and other inflammatory conditions. As with TQ0302, specific market share data is unavailable due to its developmental stage. Competitors include companies developing oral therapies and other immunomodulatory agents for SLE.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on autoimmune and inflammatory diseases is characterized by high unmet medical needs, significant R&D investment, and a competitive landscape. Advancements in understanding disease mechanisms have led to the development of targeted therapies, including biologics and small molecules. Regulatory pathways can be complex, and market access is influenced by efficacy, safety, and cost-effectiveness.
Positioning
Equillium is positioned as a company developing novel immunomodulatory therapies with the potential to address significant unmet needs in autoimmune and inflammatory diseases. Their approach targets key cellular pathways involved in immune dysregulation, differentiating them from some broad-spectrum immunosuppressants. Their competitive advantage lies in their scientific understanding of the CD6 pathway and TLR7 signaling, and their focused clinical development programs.
Total Addressable Market (TAM)
The total addressable market for autoimmune and inflammatory diseases is substantial, with billions of dollars spent annually on treatments for conditions like lupus, rheumatoid arthritis, psoriasis, and GVHD. Equillium is positioned to capture a portion of this market by developing innovative therapies for specific patient populations within these broad disease categories. The exact TAM for their specific drug candidates would depend on the approved indications and patient prevalence.
Upturn SWOT Analysis
Strengths
- Innovative therapeutic approach targeting specific immune pathways.
- Experienced management team with a track record in drug development.
- Promising clinical data for lead assets in early-stage studies.
- Intellectual property protection for its drug candidates.
Weaknesses
- Clinical-stage company with no approved products, thus no revenue from sales.
- Reliance on external funding for continued R&D and clinical trials.
- Long and complex clinical development and regulatory approval process.
- Potential for adverse events or lack of efficacy in later-stage trials.
Opportunities
- Significant unmet medical needs in target autoimmune and inflammatory diseases.
- Potential for strategic partnerships or collaborations for further development and commercialization.
- Expansion into new indications or patient populations for existing drug candidates.
- Advancements in diagnostic tools to better identify patient responders.
Threats
- Failure to demonstrate sufficient efficacy or safety in clinical trials.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Changes in regulatory requirements or reimbursement policies.
- Economic downturns impacting funding availability for biotech companies.
- Patent expirations or challenges to intellectual property.
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- AbbVie Inc. (ABBV)
- Bristol-Myers Squibb Company (BMY)
- Janssen Biotech, Inc. (part of Johnson & Johnson - JNJ)
Competitive Landscape
Equillium faces a highly competitive landscape dominated by large pharmaceutical companies with established portfolios in autoimmune and inflammatory diseases. These competitors have significant financial resources, extensive sales and marketing infrastructure, and broad product offerings. Equillium's advantages lie in its focus on potentially novel mechanisms of action and addressing specific unmet needs where existing therapies may be insufficient or have undesirable side effects. However, its disadvantages stem from its smaller size, reliance on clinical trial success, and lack of commercialization experience.
Growth Trajectory and Initiatives
Historical Growth: Equillium's historical growth has been characterized by its development from a concept into a clinical-stage biopharmaceutical company. This growth is measured by the advancement of its pipeline through preclinical and clinical stages, expansion of its scientific team, and successful fundraising efforts. Revenue growth is not applicable until product commercialization.
Future Projections: Future growth projections for Equillium Inc. are contingent on the successful progression of its drug candidates through clinical trials, obtaining regulatory approvals, and achieving successful commercial launches. Analyst estimates, if available, would typically focus on potential peak sales for approved drugs and the probability-adjusted value of their pipeline.
Recent Initiatives: Recent initiatives likely involve advancing clinical trials for TQ0302 and TQG121, potentially exploring new indications, strengthening manufacturing capabilities, and engaging with regulatory authorities. Strategic partnerships for further development or commercialization could also be a key initiative.
Summary
Equillium Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies for autoimmune and inflammatory diseases. Its strengths lie in its targeted scientific approach and promising early-stage assets. However, it faces significant challenges typical of its stage, including the high risk and cost of drug development, intense competition from larger players, and reliance on future funding. Success hinges on the successful progression of its pipeline through clinical trials and regulatory approvals.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Equillium Inc. SEC Filings (10-K, 10-Q)
- Company Investor Relations Websites
- Biopharmaceutical Industry Market Research Reports
- Financial Data Aggregators
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Equillium Inc. is a clinical-stage company, and its stock price is subject to high volatility. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data for clinical-stage companies is often estimated or not yet applicable.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Equillium Inc
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, CEO & Director Mr. Bruce D. Steel C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.equilliumbio.com |
Full time employees 35 | Website https://www.equilliumbio.com | ||
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.